DexCom (DXCM) and Great Basin Scientific (GBSN) Critical Review

DexCom (NASDAQ: DXCM) and Great Basin Scientific (NASDAQ:GBSN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares DexCom and Great Basin Scientific’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
DexCom $632.70 million 10.01 -$63.30 million ($0.77) -95.06
Great Basin Scientific $3.15 million 0.05 -$30.80 million N/A N/A

Great Basin Scientific has higher revenue, but lower earnings than DexCom.

Analyst Recommendations

This is a breakdown of current recommendations for DexCom and Great Basin Scientific, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DexCom 0 3 14 0 2.82
Great Basin Scientific 0 0 0 0 N/A

DexCom currently has a consensus target price of $87.00, suggesting a potential upside of 18.85%. Given DexCom’s higher probable upside, research analysts clearly believe DexCom is more favorable than Great Basin Scientific.

Risk and Volatility

DexCom has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Great Basin Scientific has a beta of 5.09, indicating that its share price is 409% more volatile than the S&P 500.

Profitability

This table compares DexCom and Great Basin Scientific’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DexCom -10.27% -27.90% -16.20%
Great Basin Scientific 2,588.36% N/A 168.06%

Summary

Great Basin Scientific beats DexCom on 5 of the 9 factors compared between the two stocks.

About DexCom

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company’s markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

About Great Basin Scientific

Great Basin Scientific, Inc. is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious diseases, especially hospital-acquired infections. Its commercially available tests are clostridium difficile (C. diff) and Group B Strep. Its system includes an analyzer and a diagnostic cartridge. Each analyzer contains a module into, which individual test cartridges are placed. Its other diagnostic assays in the late stages of product development include a pre-surgical nasal screen for Staphylococcus aureus (SA), food borne pathogen panel, panel for candida blood infections, test for pertussis and a test for Chlamydia tracomatis (CT)/Neisseria gonorrhea (NG). The Company also has a pipeline of assays in an early stage of development, including respiratory testing and sepsis (blood infection) panels. It markets a platform of molecular testing in small to medium sized hospitals.

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply